Logo image of ME

23ANDME HOLDING CO -CLASS A (ME) Stock Fundamental Analysis

NASDAQ:ME - US90138Q3065 - Common Stock

0.6063 USD
-0.16 (-21.26%)
Last: 3/28/2025, 8:00:00 PM
0.5 USD
-0.11 (-17.53%)
After Hours: 3/28/2025, 8:00:00 PM
Fundamental Rating

2

Taking everything into account, ME scores 2 out of 10 in our fundamental rating. ME was compared to 101 industry peers in the Health Care Providers & Services industry. The financial health of ME is average, but there are quite some concerns on its profitability. ME does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ME had negative earnings in the past year.
In the past year ME has reported a negative cash flow from operations.
In the past 5 years ME always reported negative net income.
ME had a negative operating cash flow in each of the past 5 years.
ME Yearly Net Income VS EBIT VS OCF VS FCFME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

Looking at the Return On Assets, with a value of -138.01%, ME is doing worse than 93.64% of the companies in the same industry.
ME has a Return On Equity of -545.25%. This is amonst the worse of the industry: ME underperforms 86.36% of its industry peers.
Industry RankSector Rank
ROA -138.01%
ROE -545.25%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ME Yearly ROA, ROE, ROICME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

ME has a better Gross Margin (52.58%) than 78.18% of its industry peers.
ME's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.93%
GM growth 5Y0.67%
ME Yearly Profit, Operating, Gross MarginsME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

ME does not have a ROIC to compare to the WACC, probably because it is not profitable.
ME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ME Yearly Shares OutstandingME Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 100M 200M 300M 400M
ME Yearly Total Debt VS Total AssetsME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -13.45, we must say that ME is in the distress zone and has some risk of bankruptcy.
ME has a Altman-Z score of -13.45. This is amonst the worse of the industry: ME underperforms 90.91% of its industry peers.
There is no outstanding debt for ME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.45
ROIC/WACCN/A
WACC8.71%
ME Yearly LT Debt VS Equity VS FCFME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 1.11 indicates that ME should not have too much problems paying its short term obligations.
ME has a worse Current ratio (1.11) than 68.18% of its industry peers.
ME has a Quick Ratio of 1.11. This is a bad value and indicates that ME is not financially healthy enough and could expect problems in meeting its short term obligations.
ME's Quick ratio of 0.96 is on the low side compared to the rest of the industry. ME is outperformed by 69.09% of its industry peers.
Industry RankSector Rank
Current Ratio 1.11
Quick Ratio 0.96
ME Yearly Current Assets VS Current LiabilitesME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ME have decreased strongly by -29.41% in the last year.
Looking at the last year, ME shows a very negative growth in Revenue. The Revenue has decreased by -15.83% in the last year.
Measured over the past years, ME shows a very negative growth in Revenue. The Revenue has been decreasing by -13.01% on average per year.
EPS 1Y (TTM)-29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-197.53%
Revenue 1Y (TTM)-15.83%
Revenue growth 3Y-3.43%
Revenue growth 5Y-13.01%
Sales Q2Q%34.67%

3.2 Future

The Earnings Per Share is expected to grow by 25.35% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 19.08% on average over the next years. This is quite good.
EPS Next Y-329.17%
EPS Next 2Y-99.49%
EPS Next 3Y25.35%
EPS Next 5YN/A
Revenue Next Year22.44%
Revenue Next 2Y19.85%
Revenue Next 3Y5.77%
Revenue Next 5Y19.08%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ME Yearly Revenue VS EstimatesME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
ME Yearly EPS VS EstimatesME Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ME. In the last year negative earnings were reported.
Also next year ME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ME Price Earnings VS Forward Price EarningsME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ME Per share dataME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40

4.3 Compensation for Growth

A more expensive valuation may be justified as ME's earnings are expected to grow with 25.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-99.49%
EPS Next 3Y25.35%

More info and screens

0

5. Dividend

5.1 Amount

ME does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

23ANDME HOLDING CO -CLASS A

NASDAQ:ME (3/28/2025, 8:00:00 PM)

After market: 0.5 -0.11 (-17.53%)

0.6063

-0.16 (-21.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners24.69%
Inst Owner Change-3.59%
Ins Owners9.89%
Ins Owner Change0%
Market Cap16.27M
Analysts37.78
Price Target2.12 (249.66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.94%
Min Revenue beat(2)-5.66%
Max Revenue beat(2)1.78%
Revenue beat(4)2
Avg Revenue beat(4)-4.8%
Min Revenue beat(4)-24.62%
Max Revenue beat(4)9.3%
Revenue beat(8)4
Avg Revenue beat(8)-6%
Revenue beat(12)6
Avg Revenue beat(12)-3.09%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-94.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.08
P/FCF N/A
P/OCF N/A
P/B 0.23
P/tB 0.73
EV/EBITDA N/A
EPS(TTM)-13.2
EYN/A
EPS(NY)-52.53
Fwd EYN/A
FCF(TTM)-6.05
FCFYN/A
OCF(TTM)-5.76
OCFYN/A
SpS7.78
BVpS2.62
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -138.01%
ROE -545.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.58%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.93%
GM growth 5Y0.67%
F-Score4
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.25%
Cap/Sales 3.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.11
Quick Ratio 0.96
Altman-Z -13.45
F-Score4
WACC8.71%
ROIC/WACCN/A
Cap/Depr(3y)39.05%
Cap/Depr(5y)93.91%
Cap/Sales(3y)4.44%
Cap/Sales(5y)8.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-197.53%
EPS Next Y-329.17%
EPS Next 2Y-99.49%
EPS Next 3Y25.35%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.83%
Revenue growth 3Y-3.43%
Revenue growth 5Y-13.01%
Sales Q2Q%34.67%
Revenue Next Year22.44%
Revenue Next 2Y19.85%
Revenue Next 3Y5.77%
Revenue Next 5Y19.08%
EBIT growth 1Y37.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.46%
EBIT Next 3Y21.64%
EBIT Next 5YN/A
FCF growth 1Y2.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.64%
OCF growth 3YN/A
OCF growth 5YN/A